A Study of Bimatoprost 0.01% in the Clinical Setting

Study Identifier
GMA-AP-EYE-AGN-001
CT.gov Identifier
NCT01814761
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • Bimatoprost 0.01%
    • Phase
    N/A
    Sex
    Female & Male
    Age
    20+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of primary open-angle glaucoma or ocular hypertension * Determined by the treating physician to require treatment with bimatoprost 0.01%.
    Exclusion Criteria:
    * Previous use of Lumigan® 0.01%

    Protocol Summary

    This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).

    Study Locations

    Location
    Status
    Location
    Taichung, Taiwan
    Status
    Not applicable